Combination of antibiotics

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Combination of antibiotics is one of 81 small molecule programs targeting Mortality. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MortalityNot yet recruiting

Immune ThrombocytopeniaRecruiting

MortalityPhase 3

Not yet recruiting

Immune ThrombocytopeniaPhase 3

Recruiting

Competition

Competitive Landscape

54 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Oncovin

Eli Lilly

Approved

1 5

Plaquenil

Jazz Pharmaceuticals

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Doptelet

AAkarx

Phase 3

6 9

Vyvgart

Argenx

Phase 3

5 10

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Immune Thrombocytopenia

NCT05338190

Q2 2028

Phase 3Not yet recruiting

Mortality

NCT06572761

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05338190·132 enrolled

Glioblastoma1 trial

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT03294486·78 enrolled

Mortality1 trial

A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06572761·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Combination of antibiotics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination of antibiotics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination of antibiotics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Combination of antibiotics

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Glioblastoma1 trial

Mortality1 trial

References

Drug Info

Quick Facts

Related News